非小细胞肺癌少见的EGFR外显子21 L858R复合突变与单一突变的分析研究  

Analysis of Rare Compound EGFR Exon 21 L858R Mutations and a Single Mutation of NSCLC Patients

作　　者：周欣[1] 朱红革[1] 王秀丽[1] 展翼翼 卡哈尔江.阿不都外力 卢素琼[1] 刘春玲[1] 

机构地区：[1]新疆医科大学附属肿瘤医院,830011

出　　处：《实用癌症杂志》2016年第8期1242-1246,共5页The Practical Journal of Cancer

摘　　要：目的比较了少见EGFR外显子21 L858R复合突变与单一突变的临床特征及研究两组对TKI治疗的反应。方法回顾性分析799例非小细胞肺癌患者,接受EGFR突变测试,443例患者发现有EGFR突变,其中22例(4.97%)有复合突变,详细描述6例EGFR外显子21 L858R复合突变患者和18例单一L858R突变患者的临床特征。结果疾病控制率和客观反应率L858R复合突变组和单一突变组之间没有差别。log-rank test发现,两组总生存或无疾病进展生存方面比较无显著性差异。结论复合突变组和单一突变组对EGFR TKIs反应和患者预后无显著差异。Objective To compare the rare EGFR exon 21 L858R mutation and the clinical features of a single mutation and study response of the 2 groups to TKI treatment. Methods A retrospective analysis of 799 cases of patients with non-small cell lung cancer were conducted, patients received EGFR mutation testing,443 patients had EGFR mutations ,22 cases （4.97%） had multiple mutations,detailed description of clinical features of 6 patients with compound EGFR exon 21 L858R mutations and 18 eases of patients with single L858R mutations were conducted. Results Disease control rates and objective response rate of compound L858R mutations and a single mutation had no difference. Log-rank test found that total survival or disease-free progres- sion survival had no significant difference. Conclusion Compound group and a single mutation of EGFR TKIs response and prog- nosis in patients have no significant difference.

关 键 词：非小细胞肺癌 EGFR突变 复合突变 

分 类 号：R734.2[医药卫生—肿瘤]